Please login to the form below

Not currently logged in
Email:
Password:

Algeta

This page shows the latest Algeta news and features for those working in and with pharma, biotech and healthcare.

Bayer CEO Dekkers points to 'outstanding' pharma growth

Bayer CEO Dekkers points to 'outstanding' pharma growth

9bn it paid for the drug's developer Algeta last December.

Latest news

  • Bayer buys Chinese consumer care company Bayer buys Chinese consumer care company

    Acquires Dihon Pharmaceutical as Algeta takeover closes.  . Bayer has boosted its consumer healthcare operations in emerging markets with a deal to acquire China-based Dihon Pharmaceutical Group. ... year. By the extended deadline of February 26 the

  • Bayer agrees $2.9bn deal for Algeta to get Xofigo control Bayer agrees $2.9bn deal for Algeta to get Xofigo control

    The bid represents a premium of 37 per cent over Algeta's closing price on November 25 when the initial offer was made. ... Algeta chief executive Andrew Kay said last month the drug had shown "excellent momentum" thanks to rapid endorsement by the US

  • Bayer offers $2.4bn to buy Xofigo partner Algeta Bayer offers $2.4bn to buy Xofigo partner Algeta

    Algeta made the announcement after reports in the media suggested Bayer was offering NOK 306 per share for the company. ... One unanswered question is whether Algeta has some other hidden gems in its pipeline.

  • EU approval for Bayer’s prostate cancer drug EU approval for Bayer’s prostate cancer drug

    Bayer acquired Xofigo from Norwegian company Algeta in 2009. The deal granted full commercialisation rights in Europe to Bayer while in the US Bayer co-promotes the drug with Algeta.

  • Roche's Kadcyla and Bayer's Xofigo near EU approval Roche's Kadcyla and Bayer's Xofigo near EU approval

    The CHMP also gave its blessing to Bayer and Algeta's Xofigo (radium Ra 223 dichloride) for castration-resistant prostate cancer (CRPC ). In the case of Kadcyla (trastuzumab emtansine), the CHMP ... Algeta said last month Xofigo had got off to a good

More from news
Approximately 4 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Pharma deals during June 2014 Pharma deals during June 2014

    Bayer paid 50m ($68m) upfront payment with further milestones in return for global rights which should complement Xofigo (from the acquisition of Algeta). The companies will jointly fund the phase III

  • Deal Watch table for November 2013 Deal Watch table for November 2013

    Hyperlipidemia. 2, 600. Algeta / Bayer. Acquisition. Buys out deal for Xofigo radiotherapeutic for.

  • Pharma deals during November 2013 Pharma deals during November 2013

    Algeta, has been noted as being rather ungenerous, with room for upping the offer. This takeover was an obvious tactic bringing in the key the asset, Xofigo which has been under ... with Algeta under which there was US co-promotion for 50 per cent of

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Targovax appoints chief financial officer Targovax appoints chief financial officer

    He also brings experience from cancer biotech Algeta ASA, and management consulting expertise from McKinsey &Company's pharma and healthcare practice.

  • Targovax appoints Oystein Soug as CEO Targovax appoints Oystein Soug as CEO

    He has previously served as chief financial officer for Algeta, a Norwegian oncology biotech that was bought by Bayer in 2014, and spent six years at Orkla, a Norwegian consumer goods

  • Algeta execs join Targovax Algeta execs join Targovax

    Anna-Kirsti Aksnes and Tina Madsen join the firm. Norway's Targovax has added to its senior team with the appointment of two executives from Algeta. ... Aksnes was most recently VP clinical research at Algeta, which was taken over by pharma giant Bayer

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics